India’s pharmaceutical distribution ecosystem is becoming an increasingly important arena for fintech innovation, as businesses look beyond traditional lending toward integrated commerce, payments and credit infrastructure. Against this backdrop, Mumbai-based Fundly.ai has raised $4 million in a funding round led by existing investors Accel and Multiply.
The round also saw participation from former RBL Bank executive director Rajeev Ahuja and a group of angel investors. Separately, Fundly.ai raised approximately $0.9 million in venture debt, taking the latest combined financing across equity and debt to about $4.9 million.
From Pharma Financing to a Broader B2B Platform
Founded in 2021, Fundly.ai initially focused on supply-chain finance for pharmaceutical businesses. The company has since expanded its model into three interconnected areas: B2B commerce, transaction and settlement infrastructure, and embedded credit.
This transition reflects a wider evolution in B2B fintech. Rather than treating credit as an isolated financial product, platforms are increasingly integrating financing with the transactions and commercial workflows through which businesses actually operate.
For pharmaceutical distributors and retailers, this model is particularly relevant because procurement, inventory, payments and working capital are closely connected.
Fundly.ai describes itself as a fintech platform embedded in the healthcare sector, offering financing and allied solutions for pharma distributors, retailers and other participants in the distribution ecosystem. Its current product portfolio includes lending and commerce solutions.
Capital to Expand Commerce, Payments and Credit
The newly raised capital will be used to expand Fundly.ai’s digital commerce, payments and credit offerings across India’s pharma supply chain, according to the company’s latest funding announcement.
The distinction between the two financing instruments is important. $4 million represents the funding round, while the additional approximately $0.9 million is venture debt. Therefore, describing the transaction simply as a “$4.9 million funding round” would be inaccurate.
The participation of existing investors Accel and Multiply also gives the round significance beyond its size, as both investors are backing Fundly.ai again as it broadens its business model.
Building Financial Infrastructure Around Pharma
Pharmaceutical distribution operates through a large network of manufacturers, distributors, wholesalers and retailers. For smaller businesses in this network, access to timely working capital can influence procurement capacity, inventory management and supplier payments.
Fundly.ai’s platform is designed around this financial layer. According to the company’s own website, it has supported more than 4,100 retailers and distributors across 600+ PIN codes and 24+ cities, with more than ₹1,093 crore disbursed since its inception. These are company-reported figures.
Its current offerings include supply-chain/vendor financing, working-capital solutions, payments and credit-management capabilities.
Fundly.ai’s latest raise highlights a significant direction in India’s B2B fintech market: vertical fintech is moving beyond lending.
The larger opportunity may lie in connecting credit with commerce and payments, creating financial infrastructure that is designed around the specific requirements of an industry.
For the pharmaceutical supply chain, where thousands of businesses depend on predictable inventory movement and working-capital cycles, that approach could make sector-specific fintech an increasingly important part of digital transformation.
With $4 million in fresh funding and approximately $0.9 million in additional venture debt, Fundly.ai now has additional capital to deepen its platform and expand its presence across India’s pharma distribution ecosystem.
For investors and industry leaders, the deal is another indication that India’s next B2B fintech opportunities could emerge not simply from generic financial services, but from solving specific financial and operational challenges within large, fragmented industries.
